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Background: We have reported that the glucosamine suppressed the proliferation of the human prostate carcinoma
cell line DU145 through inhibition of STAT3 signaling. DU145 cells autonomously express IL-6 and the IL-6/STAT3
signaling is activated. IL-6 receptor subunits are subject to N-glycosylation, a posttranslational modification which
is important for protein stability and function. We speculated that the inhibition of STAT3 phosphorylation by
glucosamine might be a functional consequence of the reduced N-glycosylation of gp130.
Methods: The human prostate cancer cell lines DU145 and PC-3 and human melanoma cell line A2058 were used
in this study. Glucosamine effects on N-glycosylation of glycoproteins were determined by Western blot analysis. IL-6
binding to DU145 cells was analyzed by flow cytometry. The cell proliferation suppression was investigated by
colorimetric Janus green staining method.
Results: In DU145 cells glucosamine reduced the N-glycosylation of gp130, decreased IL-6 binding to cells and
impaired the phosphorylation of JAK2, SHP2 and STAT3. Glucosamine acts in a very similar manner to tunicamycin, an
inhibitor of protein N-glycosylation. Glucosamine-mediated inhibition of N-glycosylation was neither protein- nor
cell-specific. Sensitivity of DU145, A2058 and PC-3 cells to glucosamine-induced inhibition of N-glycosylation were
well correlated to glucosamine cytotoxicity in these cells.
Conclusion: Our results suggested that the glucosamine-induced global inhibition of protein N-glycosylation might
be the basic mechanism underlying its multiple biochemical and cellular effects.
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In the previous paper [1], we reported that glucosamine
suppressed the proliferation and induced the death of
human prostate carcinoma DU145 cells. This anti-cancer
activity was associated with a decreased DNA synthesis,
cell cycle arrest in G1 phase, and induction of apoptosis.
We demonstrated for the first time that glucosamine
inhibited the phosphorylation of signal transducer and
activator of transcription (STAT) 3 at Tyr705 residue,
thereby inhibiting the STAT3 activity in DU145 [1].
STAT3, a member of the STAT family, is activated by
phosphorylation and mediates cellular responses to
cytokines and growth factors [2]. Activated STAT3
promotes angiogenesis, inflammation, proliferation and
survival of cancer cells and is frequently detected in* Correspondence: kitakura@coh.org
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distribution, and reproduction in any mediumnumerous human tumors [3]. Suppression of the STAT3
signaling pathway [4-6] therefore represents a validated
target for cancer therapy [3,7]. In DU145 cells, IL-6 is
autonomously expressed and activates the IL-6/STAT3
signaling pathway by an autocrine mechanism [8]. IL-6
first binds to the two non-signaling α-receptor subunits
(IL-6Rα/gp80) and the resultant complex recruits the
two signal transducing receptor subunits (gp130) to form
the functional ternary receptor complex. Janus kinases
(JAKs) associated with gp130 are activated by phos-
phorylation and then STAT3 becomes activated by the
phosphorylated JAKs [9].
Almost all receptors on the cell membrane are N-
linked glycosylated proteins [10]. N-linked glycosylation
(N-glycosylation) is a posttranslational modification; a
preassembled core oligosaccharide moiety (glycan) is trans-
ferred to asparagine (N) residues at potential glycosylation
sites of newly synthesized polypeptides and the attachedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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and branching [11]. N-glycosylation plays an important
role for protein stability and functions [10,12]. Taking into
account that gp130 is a highly N-glycosylated protein [13]
and that glucosamine was proposed as an inhibitor of
N-glycosylation [14], we speculated that the inhibition
of STAT3 phosphorylation by glucosamine might be a
functional consequence of the reduced N-glycosylation
of gp130.
In this paper, we revealed that in DU145 cells glucosa-
mine reduced the N-glycosylation of gp130, decreased
IL-6 binding to cells and impaired the phosphorylation
of JAK2 on Tyr1007/1008, SHP2 on Tyr542 and STAT3
on Tyr705 residues. Treatment with tunicamycin, an in-
hibitor of protein N-glycosylation [15], demonstrated all
the effects of glucosamine supporting our speculation.
We also showed that glucosamine-mediated inhibition
of N-glycosylation was neither protein- nor cell-specific.
Our results suggested that the glucosamine-induced
global inhibition of protein N-glycosylation might be
the basic mechanism underlying its multiple biochemical
and cellular effects.
Results
Glucosamine reduces the molecular mass of gp130 in DU145
cells by the inhibition of co-translational N-glycosylation
To prove our hypothesis that the inhibition of STAT3
phosphorylation by glucosamine might be a functional
consequence of the reduced N-glycosylation of gp130,
we first studied the effect of glucosamine on the gp130
expression in DU145 cells by Western blot analysis. The
treatment of DU145 cells with 2 mM glucosamine resulted
in a time-dependent accumulation of gp130 proteins with
a reduced molecular mass of 100-110 kDa (marked with
filled arrows) and the proteins with an original mass
(marked with open arrow) became undetectable after 24 h
(Figure 1A). However, the molecular mass of actin was
unaffected. The extent of gp130 molecular mass reduc-
tion was in proportional to glucosamine concentrations
(0.25-4 mM) for a 24 h treatment. At 0.25 mM, a slight
reduction of the molecular mass was observed and at
4 mM, the original gp130 proteins completely disappeared
(Figure 1B, the first row). In parallel to the reduction of
the gp130 molecular mass, the phosphorylation of STAT3
at Tyr705 residue gradually decreased (the second row). It
is noteworthy that the same range of glucosamine concen-
trations (0.5 – 4 mM) in this experiment proportionally
inhibited the proliferation of DU145 cells as published [1].
The observed reduction of gp130 molecular mass could
occur as a result of either the loss of post-translational
modifications such as N-glycosylation, proteolytic cleavage
of translated products, premature termination of transla-
tion, or a combination of these processes. Gp130 has
11 potential N-glycosylation sites and 9 of them areactually N-glycosylated [13]. To investigate the mechanism
underlying the glucosamine-induced reduction of gp130
molecular mass, DU145 cells were treated with tunicamy-
cin, a proven inhibitor of N-glycosylation [15]. As shown
in Figure 1C, the tunicamycin treatment resulted in a
gradual reduction of the molecular mass of gp130 in a
concentration-dependent manner similar to glucosamine,
albeit using about one thousandth of the concentration.
The reduction of the molecular mass was accompanied
by the suppression of STAT3 phosphorylation at Tyr705.
These results showed that glucosamine precisely repro-
duced the pattern of the tunicamycin treatment (Figures 1B,
C) and suggested that the glucosamine-induced reduction
of gp130 molecular mass was caused by the inhibition of
N-glycosylation. To exclude the possibility of proteolytic
cleavage or premature translation termination, extracts
from DU145 cells cultured in the presence or absence
of glucosamine were treated in vitro with N-glycanase F
(PNGase F), which removes N-glycans from proteins
regardless of the levels of their initial N-glycosylation
(Figure 2A). Incubation of cell extracts derived from the
untreated cells (lane 1, original gp130, open arrow) or the
glucosamine- treated cells (lane 2, gp130 with reduced
molecular mass, filled arrow) with PNGase F generated
protein products with the identical molecular mass (lane 3
and 4, filled arrow). These data proved that neither pro-
teolytic cleavage nor premature translation termination
was involved in the reduction of gp130 molecular mass in
the treatment with glucosamine. Furthermore, the treat-
ment of DU145 cells with glucosamine in the presence
of cycloheximide, a translational inhibitor, completely
abolished the appearance of gp130 proteins with lower
molecular mass (Figure 2B, lane 4). The data indicate
that glucosamine does not remove N-glycans from the
mature gp130, but inhibits N-glycosylation of the newly
synthesized protein. Finally, as shown in Figure 2C,
cytochalasin B, an inhibitor of glucose transporters [16],
blocked the glucosamine-induced reduction of the gp130
molecular mass (lane 4) suggesting that cells uptake
glucosamine by glucose transporters. Altogether, these
results clearly demonstrate that glucosamine is trans-
ported into DU145 cells via glucose transporters and
suppresses co-translational N-glycosylation to produce
gp130 proteins with a lower molecular mass.
Glucosamine-induced inhibition of N-glycosylation of gp130
represses the IL6/JAK/STAT3 signaling in DU145 cells
To determine whether the deficiency in N-glycosylation
has any effects on the activity of the gp130-associated
IL-6/JAK/STAT3 signaling [9], we carried out the fol-
lowing investigations. First, we studied IL-6 binding to
DU145 cells in the presence and absence of glucosamine.
Cells were pre-treated with glucosamine (2 mM for 24 h)















Figure 1 Glucosamine reduced the molecular mass of gp130 and suppressed the phosphorylation of STAT3 in DU145 cells. (A) Western
blot analysis of the extracts from the cells cultured in the presence of 2 mM glucosamine for the indicated time (h). Whole-cell lysates were subjected
to immunoblotting using antibodies specific for gp130 and actin (loading control). The open arrow indicates the molecular mass of gp130 without
glucosamine treatment and the filled arrow indicates the reduced molecular mass of gp130 following the treatment. (B) Western blot analysis of cells
cultured with indicated concentrations of glucosamine (mM) for 24 h. Whole-cell lysates were subjected to immunoblotting using antibodies specific
for gp130, phospho (Tyr705)-STAT3 (p-STAT3), STAT3 and actin (loading control). (C) Western blot analysis of cells cultured with indicated concentrations
of tunicamycin (μM) for 24 h. Whole-cell lysates were subjected to immunoblotting using the same antibodies as described for B. Each blot is
a representative of three independent experiments.
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of DU145 cells with glucosamine considerably shifted the
intensity of IL-6 fluorescence to a lower side indicating
less binding of IL-6 to cells as compared to the untreated
control (Figure 3A). Next, we analyzed the tyrosine
phosphorylation of the down-stream signaling molecules
of IL-6 receptor including JAK2, STAT3 and SHP2.
DU145 cells secrete IL-6, which stimulates the phosphor-
ylation of these molecules via an autocrine fashion [8]. As
shown in Figure 3B, basal levels of the phosphorylated
JAK2 (Tyr1007/1008, p-JAK2), STAT3 (Tyr705, p-STAT3)
and SHP2 (Tyr542, p-SHP2) were detected (lane 1), and
exogenous IL-6 (2 ng/ml, 15 min) further increased the
tyrosine phosphorylation of these signaling proteins (lane
2). Glucosamine treatment decreased the levels of both
the basal (lane 1 vs. 3) and IL-6-induced (lane 2 vs. 4)
tyrosine phosphorylation of JAK2, STAT3 and SHP2.
These results demonstrated that glucosamine prevented
IL-6 from binding to cells and suppressed the multiple
steps of the IL-6/JAK/STAT3 signaling pathway. To con-
firm further that the inhibition of N-glycosylation couldbe responsible for the decrease of IL-6 binding to cells
and the impairing of the IL-6/JAK/STAT3 signaling,
DU145 cells were treated with tunicamycin in a similar
way to glucosamine. The results showed that tunicamycin
reduced IL-6 binding to cells (Figure 3C) and impaired
both the basal and IL-6-induced tyrosine phosphorylation
of JAK2, STAT3 and SHP2 (Figure 3D, lane 3 and 4). We
concluded that the glucosamine-induced inhibition of
gp130 N-glycosylation reduced IL-6 binding to cells to
suppress the IL-6/JAK/STAT3 signaling pathway.
Glucosamine affects on multiple N-glycosylated proteins
To demonstrate that the glucosamine-induced inhibition
of N-glycosylation was not limited to gp130, we analyzed
the effect of glucosamine on the other N-glycosylated
protein EGFR in DU145 cells. The 170 kDa human EGFR
has 11 potential N-glycosylation sites, 8 of them are fully
glycosylated, and one site is only partially glycosylated
[17]. As shown in the upper panel of Figure 4A, treatment
of cells with glucosamine (2 mM) resulted in the reduc-
tion of the expression level of the 170 kDa EGFR protein
A.
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Figure 2 Glucosamine inhibited co-translational N-glycosylation of gp130 and glucose transporter activity was essential for the inhibition.
(A) Western blot analysis of the whole-cell lysates treated in vitro with peptide-N-glycosidase F (PNGase F). DU145 cells cultured with or without 2 mM
glucosamine for 24 h, and then whole-cell lysates were prepared and treated with or without peptide-N-glycosidase F (40 ug/ml) for 4 h at
37C followed by immunoblotting using antibodies specific for gp130 and actin (loading control). The open arrow indicates the molecular mass
of N-glycosylated gp130 without glucosamine or PNGase F treatment and the filled arrow indicates reduced molecular mass of N-glycosylation
deficient gp130. (B) Western blot analysis of cells treated with 2 mM glucosamine in the presence or absence of cycloheximide. DU145 cells
cultured with or without 2 mM glucosamine for 4 h in the presence or absence of cycloheximide (100 μg/ml), and then the whole-cell extracts
were prepared and subjected to immunoblotting using antibodies specific for gp130 and actin (loading control). The open arrow indicates
the molecular mass of N-glycosylated gp130 and the filled arrow indicates the reduced molecular mass of N-glycosylation deficient gp130. (C)
Western blot analysis of DU145 cells treated with glucosamine in the presence or absence of glucose transporter inhibitor cytochalasin B. Cells
pre-incubated with 10 μM cytochalasin B for 30 min and then treated with 2 mM glucosamine for 4 h. The whole-cell extracts were prepared
and subjected to immunoblotting using antibodies specific for gp130 and actin (loading control). The open arrow indicates the molecular mass of
N-glycosylated gp130 and the filled arrow indicates the reduced molecular mass of N-glycosylation deficient gp130. Each blot is a representative of
three independent experiments.
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with a lower molecular mass (marked with filled arrow)
in a time dependent manner as it was observed for
gp130 (Figure 1A). We verified that neither proteolytic
cleavage nor premature translation termination caused
the reduction of the molecular mass by glucosamine
(Figure 4B). Incubation of extracts from both the untreated
(lane 1) and glucosamine treated cells (lane 2) with PNGase
F gave de-N-glycosylated EGFR proteins with an identical
molecular mass (lanes 3 and 4). Since the effect on EGFR
was identical to that on gp130 (Figures 1A and 2A), we
concluded that glucosamine suppresses N-glycosylation of
EGFR. EGFR is a tyrosine kinase receptor which is activated
by autophosphorylation at Tyr845 residue upon ligand
binding [18] and we examined whether the activity was
altered by de-N-glycosylation. As shown on Figure 4A,
the non-treated 170 kDa form of EGFR was stronglyphosphorylated at Tyr 845 residue in the cells cultured
with 10% serum (lane 1 marked with open arrow),
whereas EGFR with a lower molecular mass that was
deficient in N-glycosylation was weakly phosphorylated
at this residue (lanes 2 and 3 marked with filled arrow).
To further confirm that glucosamine inhibited global
protein N-glycosylation, in addition to gp130 and EGFR,
we analyzed four other N-glycosylated proteins including
C-MET, clusterin, CD44 and MRP1 in DU145 cells.
Western blot analysis of cell extracts revealed the time
dependent increase of the mobility of those proteins in
the presence of glucosamine (Figure 5A). Taken all the
results together, we concluded that in DU145 cells
glucosamine depleted a pool of N-glycosylated proteins
by suppressing N-glycosylation of the newly synthesized
proteins. To address the functional consequence of















































Figure 3 Glucosamine suppressed the IL-6/JAK/STAT3 signaling pathway in DU145 cells. (A) Glucosamine decreased IL-6 binding to DU145
cells. Cells cultured with or without 2 mM glucosamine for 24 h, and then incubated with a fluorescently labeled IL-6 followed by FACS analysis. Gray
histogram represents IL-6 binding to cells without glucosamine treatment, bold line histogram represents IL-6 binding to glucosamine-treated cells
and dotted line histogram represents negative control, cells without fluorescently labeled IL-6. (B) Western blot analysis of cells cultured with or
without glucosamine following the IL-6 treatment. Cells cultured in serum free medium with or without 2 mM glucosamine for 24 h and then
treated with 2 ng/ml IL-6 for 15 min. Whole-cell lysates were subjected to immunoblotting using antibodies specific for gp130, phospho (Tyr1007/
1008)-JAK2 (p-JAK2), phospho (Tyr705)-STAT3 (p-STAT3), phospho (Tyr542)-SHP2 (p-SHP2) and actin (loading control). The open arrow indicates
N-glycosylated gp130 and the filled arrow indicates N-glycosylation deficient gp130. (C) Tunicamycin decreases IL-6 binding to DU145 cells.
Cells were cultured with or without 1 μg/ml tunicamycin for 24 h and then incubated with a fluorescently labeled IL-6 following FACS analysis.
Gray histogram represents IL-6 binding to cells without tunicamycin treatment, bold line histogram represents IL-6 binding to tunicamycin-treated cells
and dotted line histogram represents negative control, cells without fluorescently labeled IL-6. (D) Western blot analysis of cells cultured with or
without tunicamycin followed by the IL-6 treatment. Cells cultured in serum free medium with or without 1 μg/ml tunicamycin for 24 h and
then treated with 2 ng/ml IL-6 for 15 min. Whole-cell lysates were analyzed and data were presented in the same way as for glucosamine
(Figure 3B). The binding assays and each blot are a representative of three independent experiments.
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http://www.cancerci.com/content/14/1/45N-glycosylation, we examined the phosphorylation (activity)
of three important signaling proteins in cancer cells, STAT3
(Tyr705), AKT (Ser473) and ERK1/2 (Thr202/Tyr204) that
were activated by membrane N-glycosylated receptors.
We found that phosphorylation of all these proteins incells cultured with serum (10% FBS) was suppressed by
the treatment of 2 mM glucosamine in a time dependent
manner (Figure 5B, lanes 2 and 3). These data suggest that
suppression of multiple signaling pathways may contribute














Figure 4 Glucosamine inhibited N-glycosylation and auto-
phosphorylation of EGFR in DU145 cells. (A) Western blot analysis
of cells cultured in the presence of 2 mM glucosamine for 24 or 48 h.
Whole-cell lysates were subjected to immunoblotting using antibodies
specific for EGFR, phospho (Tyr845)-EGFR (pEGFR) and actin (loading
control). The open arrow indicates the N-glycosylated receptor and its
phosphorylated form, and the filled arrow indicates the N-glycosylation
deficient receptor and its phosphorylated form. (B) Western blot
analysis of the whole-cell lysates treated in vitro with peptide-N-
glycosidase F (PNGase F). DU145 cells cultured with or without
2 mM glucosamine for 24 h, and then the whole-cell lysates were
prepared and treated with or without peptide-N-glycosidase F (40 ug/ml)
for 4 h at 37C followed by immunoblotting using antibodies specific for
EGFR and actin (loading control). The open arrow indicates the molecular
mass of N-glycosylated EGFR and the filled arrow indicates the reduced
molecular mass of N-glycosylation deficient EGFR. Each blot is a
representative of three independent experiments.
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of N-glycosylation is correlated to glucosamine
anti-cancer activity
To examine whether the inhibition of N-glycosylation is
cell-specific, we compared the sensitivity of two human
prostate carcinoma DU145 and PC-3 cells and human
melanoma A2058 cells to glucosamine. The cells were
cultured in 0.5, 1, 2, or 4 mM glucosamine for 4 h, and
the inhibition of N-glycosylation was assessed by Western
blot analysis of clusterin. As shown in Figure 6A, an
increased mobility of clusterin with the inhibition of N-
glycosylation was detected at 1 mM, 2 mM and 4 mM
in DU145 cells, A2058 cells and PC-3 cells, respectively.
Western blot analysis of the others N-glycosylated pro-
teins (gp130 and EGFR) in the respective cells produced
the results identical to clusterin (data not shown). These
data indicate that DU145 cells were the most sensitive to
the glucosamine-induced inhibition of N-glycosylation,
followed by A2058 cells, and PC-3 cells were the least
sensitive. To investigate whether the inhibition of N-
glycosylation correlated to the anti-cancer activity of
glucosamine, we carried out cell viability assays of these
cells under the same conditions. As shown in Figure 6B,
the toxicity of glucosamine to DU145, A2058 and PC-3
cells correlated directly with the inhibition of N-glyco-
sylation. These results suggest that the glucosamine-
induced inhibition of protein N-glycosylation might be
one of the basic mechanisms that accounts for the
glucosamine anti-cancer activity.
Discussion
Glucosamine, an amino monosaccharide has been widely
used as a dietary supplement to relieve discomfort of
rheumatoid arthritis or osteoarthritis for more than fifty
years [19]. Glucosamine has also been reported as an
inhibitor of tumor growth both in vivo [20] and in vitro
[21]. However, the mechanism for the anti-cancer activity
is still not fully understood to explore the potentials of
glucosamine as an anti-cancer agent. Previously [1], we
have proposed our hypothesis that glucosamine could
inhibit the N-glycosylation of IL-6 receptor in human
prostate carcinoma DU145 cells, thereby reducing the
activity of the IL-6/JAK/STAT3 signaling pathway. This
pathway is activated and contributes to carcinogenesis
in many different tumors. This study focused on proving
our hypothesis and examining the mechanism by which
the STAT3 activity is suppressed by glucosamine. When
DU145 cells were treated with glucosamine, Western blot
analysis showed that several gp130 proteins with a lower
molecular mass appeared in a time and dose dependent
manner (Figure 1). In the following experiments, we dem-
onstrated that digestion of the extracts from the untreated
and glucosamine-treated DU145 cells with peptide-N-

















Figure 5 Glucosamine reduced the molecular mass of various
glycoproteins by inhibiting N-glycosylation and suppressed the
multiple signaling pathways in DU145 cells. (A) Western blot
analysis of cells cultured in the presence of 2 mM glucosamine
for 24 or 48 h. Whole-cell lysates were prepared and subjected to
immunoblotting using antibodies specific for c-MET, CD 44, clusterin,
MRP1 and actin (loading control). The open arrow indicates the
molecular mass of proteins without glucosamine treatment and the
filled arrow indicates the reduced molecular mass of protein following
the treatment. (B) Western blot analysis of the phosphorylated (active)
STAT, AKT and ERK1/2 proteins after glucosamine treatment. The whole-
cell lysates employed in Figure 5A were subjected to immunoblotting
using antibodies specific for phospho (Tyr705)-STAT3 (pSTAT3),
phospho (Ser473)-AKT (pAKT), phospho (Thr202/Tyr204)-ERK1/2
(pERK1/2) and actin (loading control). Each blot is a representative
of three independent experiments.
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on Western blot gels regardless of the mobility of the
proteins before the digestion. These results indicated
that gp130 proteins with a lower molecular mass had
less N-glycosylated sites and therefore, were not trun-
cated products of translation step. Furthermore, the
glucosamine treatment of DU145 cells in the presence
of cycloheximide did not produce any gp130 proteins
with a lower molecular mass suggesting that glucosa-
mine inhibited N-glycosylation of the newly synthesized
protein but did not remove N-glycans from the mature
gp130 (Figure 2). IL-6 receptor is composed of four
subunits, two gp80 subunits containing the IL-6 binding
domain and two gp130 subunits containing the signal
transducing domain. Flow cytometry binding assays
showed that IL-6 bound weakly to cells treated with
glucosamine. We speculated that the gp130 subunit
deficient in N-glycosylation could not form the intact
IL-6 receptor with the gp80 subunit and thereby the
binding of IL-6 to cells was suppressed to reduce the
signal transduction. It was shown that N-glycosylation-
deficient gp130 after tunicamycin treatment lost the ability
to form a heterodimer with the leukemia inhibitory factor
(LIF) binding subunit, and lost the signal transduction in
response to LIF in neuroepithelial cells [23]. To further
confirm that glucosamine acts in a similar manner to tuni-
camycin, we carried out the same experiments described
above using tunicamycin in place of glucosamine. Tuni-
camycin is a proven inhibitor of protein N-glycosylation
which blocks the transfer of N-acetylglucosamine to
dolichol in the first step of oligosaccharide synthesis
[15]. Indeed, tunicamycin lowered the molecular mass
of the normally expressed gp130, suppressed IL-6 bind-
ing to cells and reduced the activity of the IL-6/JAK/
STAT3 signaling pathway in a dose dependent manner
like glucosamine (Figure 1C, 3). Obviously, various proteins
are N-glycosylated and the modification of proteins by
N-glycosylation is not specific to gp130. To confirm
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Figure 6 The sensitivity of cells to the inhibition of N-
glycosylation by glucosamine was correlated to glucosamine
toxicity. (A) Western blot analysis of DU145, A2058 and PC-3 cells
cultured with the indicated concentrations of glucosamine (mM)
for 4 h. Whole-cell lysates were subjected to immunoblotting using
antibodies specific for clusterin as N-glycosylation marker. The open
arrow indicates the molecular mass of N-glycosylated clusterin and
the filled arrow indicates N-glycosylation deficient clusterin. Each blot
is a representative of three independent experiments. (B) The viability
of DU145, A2058 and PC-3 cells cultured in the presence of the
indicated concentration (mM) of glucosamine for 48 h. The viability
of cells was measured by cell counting using the colorimetric Janus
green whole-cell stain method. The results were present as mean+/-SD
of four independent experiments.
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of several glycoproteins, EGFR, c-MET, CD44, clusterin
and MRP1 after the glucosamine treatment. In addition
to gp130, the treatment produced these glycoproteins with
a lower molecular mass in a different extent (Figure 5A).
Since most of cell-surface receptors are N-glycosylated
[10], it was expected that multiple signaling pathways
activated from these receptors were affected by glucosa-
mine. Indeed, Western blot analysis showed that in
addition to STAT3, the phosphorylation (activity) of other
proteins playing key signaling roles in cancer cells, AKT
and ERK1/2, were suppressed after the treatment with
glucosamine in DU145 cells (Figure 5B). These resultssuggest that glucosamine-induced inhibition of global
protein N-glycosylation might be the basic mechanism
of multiple biochemical and cellular events of its anti-
cancer action. In fact, the sensitivity of different cells to
glucosamine measured by de-N-glycosylation of clusterin
was in a good agreement with their viability (Figure 6).
As it was proposed, targeting multiple signaling path-
ways by disrupting posttranslational N-glycosylation in
a combination with other agents might be an effective
strategy for cancer therapy [24]. For example, tunicamycin
treatment enhanced the susceptibility of human non-
small cell lung cancer cells to EGFR tyrosine kinase
inhibitor erlotinib [25], and also stimulated TRAIL–
induced apoptosis in human prostate cancer PC-3 cells
[26]. Unfortunately, tunicamycin is too toxic to use for the
human treatment [27]. Alternatively, glucosamine could
be a candidate for clinical use as an inhibitor of posttrans-
lational N-glycosylation because of its low toxicity to
the normal cells and enhanced uptaken by tumor cells
due to “Warburg effect” [28]. We will investigate this
possibility and study the mechanism underlying inhib-
ition of N-glycosylation by glucosamine.
Conclusions
Current study found that, in human prostate carcinoma
cell line DU145, glucosamine reduced N-glycosylation of
IL-6 receptor subunit gp130 by inhibiting co-translational
N-glycosylation, resulting in less IL-6 binding to cells
and less phosphorylation (activation) of down-stream
JAK2 and STAT3 proteins. Our results demonstrated
that glucosamine-mediated inhibition of N-glycosylation
was neither protein- nor cell-specific. Glucosamine induced
global inhibition of protein N-glycosylation in all three
cancer cell lines which were used in this study. Several
important signals, such as STAT3, AKT and ERK1/2, were
activated by N-glycosylated membrane receptors. The
treatment of glucosamine led to the suppression of these
signals, suggesting that the glucosamine-induced inhib-
ition of N-glycosylation might be the basic mechanism
underlying its biochemical and cellular effects.
Methods
Cell culture, chemical compounds and biological reagents
The human prostate cancer DU145 and PC3 cells and
human melanoma A2058 cells were obtained from the
American Type Culture Collection. Cells were cultured in
RPMI medium 1640 supplemented with glutamine, essen-
tial amino acids, 10% fetal bovine serum and antibiotics
(100 units/ml penicillin G and 100 ug/ml streptomycin
sulfates). Cells were incubated at 37°C in 5% CO2, and the
medium was changed every 3-4 days. Cells were passaged
at 70% confluent using trypsin/EDTA. Treatments of cells
with D-glucosamine hydrochloride, tunicamycin, cyclo-
heximide, cytochalasin B and interleukin-6 (IL-6) were
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D-glucosamine hydrochloride, tunicamycin, cycloheximide,
propidium iodide and cytochalasin B were purchased from
Sigma Chemical Co., (St. Louis, MO; G-1514, T-7765,
C-4859, C-6762, P-1607, and C2743). IL-6 and Human
IL-6 Flow cytometry Kit were purchased from R & D
Systems (Minneapolis, MN; 206-IL, NF600). Peptide: N-
glycanase F (PNGase F) was purchased from New England
Biolabs (Ipswich, MA; PO704). Antibodies used for
immunoblot (Western) analysis included anti-gp130,
anti-clusterin (Millipore, Danvers, MA; 06-291, 05-354),
anti-STAT3, anti-phospho (Tyr705)-STAT3, anti-phos-
pho (Tyr1007/1008)-JAK2, anti-phospho (Tyr542)-SHP2,
anti-EGFR, anti-phospho (Tyr845)-EGFR, anti-phospho
(Ser473)-AKT, anti-phospho (Thr202/Tyr204)-ERK1/2,
anti-c-Met, anti-CD44, anti-mouse IgG HRP-linked and
anti-rat IgG HRP-linked from Cell Signaling Technology
(Beverly, MA; 9132, 9145, 3771, 3751, 2232, 2231, 4060,
4370, 3127, 5640, 7076, 7077), anti-actin and anti-MRP1
from Santa Cruz Biotechnology (Santa Cruz, CA; 1615,
59607). Additionally, Janus Green whole-cell stain was
purchased from ThermoScientific-Pierce (Rockford, IL;
62203).
Western blotting
After removing the culture medium cells in 6-well plates
were washed with 1× PBS and then lysed in the wells
with 0.1 ml of RIPA lysis and extraction buffer (25 mM
Tris-HCl, 150 mM NaCl, 1% NP-40, 1% Sodium deoxy-
cholate, 0.1% SDS, pH 7.6, (G-Bioscience, St. Louis, MO;
786-489,) supplemented with protease and phosphatase
inhibitor cocktail (ThermoScientific-Pierce, Rockford, IL;
78440) for 15 min at 4°C. Lysates were then transferred
to 1.5 ml microcentrifuge tubes, vortexed at maximum
speed for 15 sec to shear DNA and centrifuged at
12000 g for 10 min at 4°C. Supernatants were quantified
for protein concentrations by BCA protein assay kit
(ThermoScientific-Pierce, Rockford, IL; 23227) and stored
at -80°C in aliquots or used immediately for SDS-PAGE.
The samples for SDS-PAGE were prepared by incubating
with 4% SDS at 37°C for 30 min for solubilizing N-
glycosylation deficient proteins and then boiling in the
sample buffer (50 mM Tris-HCI pH 6.8, 2% SDS, 10%
glycerol, 1% β-mercaptoethanol, 12.5 mM EDTA, 0.02%
bromophenol blue) for 5 min. Equal amounts of pro-
teins were then loaded onto 8% precast SDS-PAGE gels
(ThermoScientific-Pierce, Rockford, IL; 25200). Immuno-
blotting was performed after the electrophoretic transfer
of proteins onto nitrocellulose membrane (Bio-Rad
Laboratories, Hercules, CA; 162-0115). The proteins
were detected using protein-specific first antibodies,
horseradish peroxidase-conjugated second antibodies and
chemiluminescent detection reagent (Denville Scientific,
Metuchen, NJ; E2500) according to the manufacturer’sconditions. Protein sizes on nitrocellulose membranes
were detected by protein markers (Bio-Rad Laboratories,
Hercules, CA; 161-0374). To reuse, nitrocellulose mem-
branes were washed with western blot stripping buffer
(ThermoScientific-Pierce, Rockford, IL; 46430) and blocked
again.
Peptide: N-glycanase F (PNGase F) treatment
To remove N-glycans from glycoproteins in vitro aliquots
of whole cell extracts in RIPA buffer were incubated
with Peptide:N-glycanase F (40 μg/μl) at 37°C for 4 h
and then stored at -80°C or used immediately for Western
blot analysis.
Evaluation of IL-6 binding to DU145 cells by flow cytometry
The Human IL-6 Flow Cytometry Kit (R & D Systems)
was utilized for analysis of IL-6 binding according to the
manufacturer’s protocol with slight modifications. Briefly,
DU145 cells were harvested by the treatment with 1 mM
EDTA for 3-5 min, washed two times with phosphate-
buffered saline (PBS), resuspended in PBS (4× 106/ml)
and followed by the incubation of 50 μl of cells for
1 hour at 4°C with either 20 μl of biotinylated IL-6 or
20 μl of biotinylated negative control reagent. 20ul of
Avidin-fluorescein was then added to each set of cells
and incubation was continued for a further 30 minutes
at 4°C. Cells were then washed two times with the
supplied wash buffer, resuspended with 300 μl of wash
buffer containing 10 ug/ml propidium iodide (PI) to
identify dead cells and examined by flow cytometry. A
total of 40000 cells were counted for each analysis. PI-
positive/dead cells were subsequently excluded from
the IL-6 binding examination. Fluorescence was mea-
sured using the CyAn System with Summit software
(Beckman Coulter, Brea, CA).
Cell growth suppression analysis
DU145, PC-3 or A2058 cells were plated in 96-well
plates in a complete culture medium with or without
different amount of glucosamine. Two days later, the
relative cell numbers per well were determined by the
colorimetric Janus green whole-cell stain method. Briefly,
culture medium was removed from cell layers, then cells
were fixed with 4% formaldehyde (Thermo Scientific,
Rockford, IL; 28906) for 30 min at room temperature, and
followed by vacuum aspiration of the fixative. Subse-
quently, fixed cell layers were stained with Janus Green
Whole-Cell Stain solution (Thermo Scientific, Rockford,
IL; 62203) for 5 min at room temperature. Then the
excess stain was removed by vacuum aspiration and cells
were washed 4 times with water. The dyes associated with
cell layers were then eluted by the addition of 100 μl of
0.5 N HCl per well and shaking the plates at room
temperature for 1 h. The colored dye solutions were read
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Cambridge UK) at 615 nm. Results were expressed as a
percentage of the control without glucosamine. Data were
represented as mean +/- standard deviation (SD) from
quadruplicate wells. Each cell line was analyzed in three
independent experiments.
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